ArticleAmerican journal of translational research2015
HLA-G impairs host immune response and predicts poor prognosis in pancreatic cancer.
Article in American journal of translational research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prognostic value of human leukocyte antigen G expression in solid tumors: a systematic review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Prognostic and Clinicopathological Value of Human Leukocyte Antigen G in Gastrointestinal Cancers: A Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Multimodal characterization of HLA-G expression across solid tumors reveals transcript-protein discordance and implications for immunotherapy targeting.Frontiers in immunology · 2026Article
- Harnessing the potential of HLA-G in cancer therapy: advances, challenges, and prospects.Journal of translational medicine · 2024Review
- The Immune Landscape of Human Pancreatic Ductal Carcinoma: Key Players, Clinical Implications, and Challenges.Cancers · 2022Review
- A Critical Assessment of the Association between HLA-G Expression by Carcinomas and Clinical Outcome.International journal of molecular sciences · 2021Review
- HLA-G/ILTs Targeted Solid Cancer Immunotherapy: Opportunities and Challenges.Frontiers in immunology · 2021Review
- Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients.Cancer science · 2020Observational
- The Role of HLA-G in Tumor Escape: Manipulating the Phenotype and Function of Immune Cells.Frontiers in oncology · 2020Review
- HLA-G Neo-Expression on Tumors.Frontiers in immunology · 2020Review
- European Patent in Immunoncology: From Immunological Principles of Implantation to Cancer Treatment.International journal of molecular sciences · 2019Review
- Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma.Clinical and translational medicine · 2019Review
- Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges.Frontiers in immunology · 2018Review
- Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment.International journal of molecular sciences · 2017Review
- Recent Advances in Our Understanding of HLA-G Biology: Lessons from a Wide Spectrum of Human Diseases.Journal of immunology research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human leucocyte antigen G (HLA-G) was shown to be associated with immune suppression and unfavorable prognosis in multiple types of cancers. However, its expression in pancreatic cancer (PC) was less investigated. Particularly, its roles in PC remain unknown. The present study aimed to address the issues. Expression of HLA-G was detected by Western blot and tissue microarray-based immunohistochemical staining in 10 and 158 patients with PC, respectively. In addition, tumor infiltrating lymphocytes (TIL) labeled by CD3 staining, as a marker of host immune response, were counted. Finally, immunohistochemical HLA-G expression was linked to clinicopathologic variables, TIL number and overall survival. It was found that HLA-G was overexpressed in 4 out of 10 patients. For staining, HLA-G expression was much higher in tumor than in non-tumor tissues. Tumoral expression of HLA-G was closely associated with T stage. Intratumoral CD3-positive TIL in tumors with diffuse HLA-G expression was less than that in those with negative or local HLA-G expression, but no significant differences for stromal TIL were observed. Univariate analysis found that diffuse HLA-G expression in tumor tissues and low intratumoral CD3-positive TIL number were of predictive significance for poor overall survival of PC. Furthermore, HLA-G expression and intratumoral CD3-positive TIL number were identified, by multivariate Cox regression test, as independent prognostic factors. Our data suggest that HLA-G impairs host immune response and predicts poor prognosis in PC.
Indexed as
Identifiers
26692947PMC4656780What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.